The Impact of Intracervical Terlipressin on Intravasation and Venous Embolization During Transcervical Myomectomy and Endometrium Resection: A Randomized Controlled Study

What Was Tested

This randomized controlled trial paper looks at Terlipressin in the context of endometriosis.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, women only.

Patients who were scheduled for transcervical resection of type 1 or type 2 myomas (TCR-M), or for extensive transcervical endometrium resection (TCR-E).

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Terlipressin group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Terlipressin.

Some participants received a placebo instead of Terlipressin, giving a reference point.

Gynecologic surgical unit in a general hospital.

The amount of intravasation and level of COHb was measured at the end of the procedure.

The incidence and severity of gas embolisms was determined during the procedure by transesophageal echocardiography (TEE).

Study groups were compared using an Independent Samples T-Test or a Mann-Whitney U test as indicated.

What Was Measured

Topics PubMed links to this paper include Uterine Myomectomy, Terlipressin, Vasoconstrictor Agents, Uterine Neoplasms, Leiomyoma, Embolism, Air and Hysteroscopy.

Author keywords: COHb, Gas embolisms, TCR-E and TCR-M.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Terlipressin in people with endometriosis.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Journal of minimally invasive gynecology), a journal based in United States.

More context: the Terlipressin compound page, Endometriosis research.